T Cell-Dependent Mechanism + CD 8 B 7-1-Transfected P 815 Tumor Cells Via a Contribute to the Eradication of Host B 7-1 and B 7-2 Costimulatory Molecules and

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Triggering of natural killer cell mediated cytotoxicity by costimulatory molecules.

  1998cited by this paper
• Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

  1998cited by this paper
• B7-negative versus B7-positive P815 tumor: differential requirements for priming of an antitumor immune response in lymph nodes.

  1997cited by this paper
• Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines.

  1997cited by this paper
• Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells.

  1997cited by this paper
• Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules.

  1996cited by this paper
• CD80 (B7.1) and CD54 (intracellular adhesion molecule-1) induce target cell susceptibility to promiscuous cytotoxic T cell lysis.

  1996cited by this paper
• Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?

  1996cited by this paper
• Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization.

  1996cited by this paper
• A new foreign policy: MHC class I molecules monitor the outside world.

  1996cited by this paper
• B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes

  1996cited by this paper
• Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 costimulatory molecule

  1996cited by this paper
• B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct.

  1996cited by this paper
• Expression of B7-1 by highly metastatic mouse T lymphomas induces optimal natural killer cell-mediated cytotoxicity.

  1995cited by this paper
• A reassessment of the role of B7-1 expression in tumor rejection

  1995cited by this paper
• Manipulation of costimulatory signals to enhance antitumor T-cell responses.

  1995cited by this paper
• Analysis of lymphocyte costimulation in vivo using transgenic and 'knockout' mice.

  1995cited by this paper
• New perspectives of CD28-B7-mediated T cell costimulation.

  1995cited by this paper
• CD28-mediated costimulation is necessary for optimal proliferation of murine NK cells.

  1994cited by this paper
• Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity

  1994cited by this paper
• Signals and signs for lymphocyte responses.

  1994cited by this paper
• Specificity and longevity of antitumor immune responses induced by B7-transfected tumors.

  1994cited by this paper
• Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells.

  1993cited by this paper
• CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help

  1993cited by this paper
• Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice.

  1993cited by this paper
• Costimulation of T cells for tumor immunity.

  1993cited by this paper
• Molecules involved in T-cell costimulation.

  1993cited by this paper
• Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy.

  1992cited by this paper
• Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4.

  1992cited by this paper
• Expression and function of the murine B7 antigen, the major costimulatory molecule expressed by peritoneal exudate cells.

  1992cited by this paper
• Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation

  1991cited by this paper
• Alloreactive murine CD8+ T cell clones secrete the Th1 pattern of cytokines.

  1990cited by this paper
• Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells

  1990cited by this paper
• Recruitment and activation of tumor-specific immune T cells in situ. CD8+ cells predominate the secondary response in sponge matrices and exert both delayed-type hypersensitivity-like and cytotoxic T lymphocyte activity.

  1989cited by this paper
• Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide.

  1986cited by this paper
• Preparation of immunotherapeutic autologous tumor cell vaccines from solid tumors.

  1979cited by this paper

• B7 Family Molecules Are Favorably Positioned at the Human Maternal-Fetal Interface1

  2003cites this paper
• Expression in P 815 Tumor Cells Mechanism of Melphalan-Induced B 7-1 Gene Bluestone and

  2001cites this paper
• TumorUp-Regulate B 7-1 Gene Expression in Melphalan and Other Anticancer Modalities and

  2000cites this paper
• Costimulation Tumor Cells Is Absolutely Dependent on Cytotoxic CD 8 Cells to Allogeneic P 815 CD 4 Help-Independent Induction of Sutherland and

  2000influential citation